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Abstract
In mammalian development, a complex system comprised of regulatory signals causes
tissue distinction with unique structures as well as functions. Gene expression controls these
functions through specific combinations of transcription factors and cofactors that influence cell
differentiation by both activation and repression of genes.
Whole genome microarray studies of fibroblasts have identified candidate genes that can
serve as master regulators of fibroblast identity. A previous study showed that Prrx1 and Snai2
play important roles in activating expression of fibroblast identity, and Snai2 overexpression in
hepatoma cells (Fg14) activated expression of fibroblast specific genes. Moreover, Snai2
overexpression resulted in repression of liver specific genes. This thesis addresses whether
Twist1 has a similar effect as Snai2. More specifically, the objective of this work is to determine
how Twist1 transfection of hepatoma cells (Fg14) affects fibroblast specific and hepatoma
specific genes.
qPCR analysis revealed that Twist1 was successfully over-expressed in pooled Fg14
transfectants and individual clones compared to the non-transfected cells. Following these
experiments, expression of several important genes in hepatic and fibroblast function were
monitored. Results show that, of the 7 fibroblast specific genes tested, Twist1 overexpression
activated two genes, Prrx1 and Sema3a, in Fg14 hepatoma cells. However, the remaining 5
fibroblast genes were not affected. Twist1 overexpression was found to not affect expression of
the 10 hepatoma-specific genes tested.
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Based on these results, unlike results obtained with Snai2 and Prrx1 overexpression
studies, Twist1appears to have limited potential to reprogram hepatoma cells toward the
fibroblast phenotype.
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Chapter 1
Introduction
1.1. Gene Regulation in Multicellular Organisms
It is vital to have an in-depth comprehension of gene regulation to better understand many
processes in life organisms. The discovery of the molecular machines that transcribe human genes,
namely RNA polymerases I, II and III (Pol I, II and III), was a milestone in the research area of
eukaryotic transcription [1][2][3] and paved the way to understanding the evolution of
transcriptional regulation in eukaryotes. One of the main challenges in the area is to identify all
the functional elements in this very complex genome, a subset of which is functional elements[4].
The expression of eukaryotic protein-coding genes occur mostly at the transcription
initiation level. Most eukaryotic genes are transcribed by RNA polymerase II and regulated by
two separate families of DNA sequences which are both cis-acting elements that have recognition
sites to amplify or suppress transcription. The first family belongs to a promoter that contains a
core promoter and nearby regulatory elements, whereas the second family belongs to distal
regulatory elements such as enhancers, silencers, insulators and locus control regions (LCR). An
illustration of a typical gene regulatory elements is given in Figure 1[4] and more details are
presented in the next section.
There is much variation in eukaryotes in the quantity of the genes that are transcribed into
both coding and noncoding RNA species[5]. The human genome has roughly 20,000 proteincoding genes and even more non protein-coding genes (ncRNA)[6]. Several ncRNAs have been
shown to take part in gene expression control via modulation of transcriptional or
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posttranscriptional processes such as fine tuning the levels of target messenger RNAs (mRNAs)
or selecting chromatin regulators to modify gene expression[7].

Figure 1. Schematic of gene regulatory elements. Taken from[4]

Three groups play a role in accurate transcription in eukaryotic cells. These are: general
transcription factors (GTF) activators which are promoter-specific proteins and coactivators. GTFs
gather around the core promoter in order to form a transcription preinitiation complex (PIC) which
leads RNA polymerase II to the transcription initiation site. A complete RNA polymerase II
elongation complex occurs after several steps including promoter melting, clearance, and
escape[8]. PIC sitting on the core promoter is only enough for low levels of basic transcription. In
order to trigger more transcription activity, the second group (activators) come into play..
Activators are sequence-specific proteins with separable activation domain[9]. Activators are
believed to work by increasing PIC formation through the interactions with transcriptional
targets[10]. The last group that plays a role in correct transcription is coactivators. Coactivators do
not have sequence-specific DNA binding, they are used by DNA-bound activators[11]. Although
different in structure, coactivators’ functions are very similar to activators which stimulate PIC
formation and modify chromatin.
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1.2. The Elements of Transcriptional Regulation
There are six different elements that have a significant role in the transcription process as
can be seen in Figure 1. The first one is the core promoter which is described as the region at the
starting point of a gene that acts as the docking site for both the PIC assembly and basic
transcriptional machinery. It dictates position and direction of the transcription[12]. The second
element is the proximal promoter which is the region that neighbors upstream from the core
promoter. One important characteristic is to house activators via their binding sites[4]. The core
promoter and the proximal promoter together make up the promoter part.
The remaining four elements are called distal regulatory elements. An interesting question
to ask can be how these distal regulatory elements function from a distance. According to studies,
DNA-looping, in which the DNA loops out so that core promoter and distal elements can be
brought together is responsible[13]. Of them, enhancers increase the transcription capacity and
perform similar to proximal promoter[14][15]. They regulate the transcription in a spatial or
temporal-specific way and work regardless of the distance or orientation of the promoter[15]. The
second distal regulatory element is silencers which have similar structure but act in the opposite
way of enhancers. They house binding sites for repressors which are negative transcription
factors[16]. Another element is insulators that block the genes from being affected by the
neighboring genes. This effectively limits the affecting boundary of the other regulatory
elements[4]. Two main characteristic of insulators are blocking enhancer-promoter
communication and averting the spread of suppressive chromatin. Insulators are also called
boundary elements. The last element in this category is locus control regions (LCRs). As the name
suggests, they regulate an entire locus or gene cluster[17] with enhancing specific activity being
the most important characteristic. They function in a similar way to enhancers and silencers.
3

Figure 2. Distal transcriptional regulatory elements and their functions of each. Taken
from[4]

1.3. Transcription Factors and Gene Regulation
Transcription factors bind to DNA by occupying DNA sequences at control elements (ciselements) where they make use of and regulate the transcription apparatus[5]. Transcriptional
regulation occurs at two different but interconnected levels. The first level includes transcription
factors and transcription apparatus whereas the second level includes chromatin and its
regulators[5] (Figure3).
Transcription factors regulate gene expression through binding to enhancer elements and
selecting RNA polymerase II and cofactors to target genes[18]. Transcription factors regulate
transcription by synergistically binding to individual enhancers from core promoters via physical
contact which involves looping of the DNA that contains enhancers and the core promoters[19].

4

As mentioned before, transcription factors bind to cofactors which are protein complexes
that leads to activation (termed coactivators) and repression (termed corepressors). By making use
of coactivators, transcription factors are believed to assist transcription initiation. After the
transcription is initiated by RNA polymerase II, only a short distance of 20 to 50 bp is transcribed
due to pause control factors. At the next step, these paused polymerases transition to elongation
with the help of positive transcription elongation factor b (P-TEFb) which can be a component of
super elongation complex (SEC).
The second level of transcriptional regulation involves chromatin (Figure 3, right). The
main unit of chromatin is the nucleosome that is governed by protein complexes capable of
mobilizing and altering its histone components. Mobilizing nucleosomes with the help of ATPdependent chromatin complexes help them access to the transcription apparatus A[20]. There are
also a variety of histone-modifying enzymes that modify nucleosomes of each active gene[21].
The alteration helps create a dynamic environment for chromatin modification as RNA polymerase
is used in the process of initiation and elongation of the RNA species. There are several types of
repressed chromatin[22] which are embedded: one type contains nucleosome alterations by the
Polycomb complex which are silent but ready for activation at later stages of development[23] and
the other type is completely silenced[24].

5

Figure 3. Schematic of transcriptional regulation. Taken from[5]

1.4. Liver Development and Hepatocellular Carcinoma
Being the largest gland in mammals, the liver has endocrine functions such as insulin-like
growth factors, angiotensinogen, and thrombopoietin secretion and exocrine properties like bile
secretion[25]. It is the main player in a variety of bodily functions such as glycogen storage, drug
detoxification, metabolism control, overseeing cholesterol synthesis and transport and plasma
protein secretion. Liver diseases such as hepatic fibrosis, cirrhosis and hepatitis tend to have a high
morbidity rate and are reported to be the fourth leading cause of death in the United States among
middle-aged people[25]. Comprising 2-5% of the whole body mass and being mostly made from
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hepatocytes, this organ is responsible for many functions, including purification of proteins and
production of growth factors, signaling molecules and hormones.
Being mostly comprised of hepatocytes, the liver has a very complicated tissue
architecture. The liver lobule can be thought of the main building block of the liver. Plates of
hepatocytes are separated by sinusoidal capillaries are arranged around central veins. Hepatocytes
make up 78% of the liver and are responsible for protein and bile secretion, detoxification,
cholesterol, urea and glucose regulation, acute phase response and blood clotting[26]. There are
other types of cells in the liver. Cholangiocytes (bile duct cells) make up 3% of the liver and form
bile ducts, control bile flow and pH and secrete water and bicarbonate as necessary. Endothelial
cells line the lumen of blood vessels. Sinusoidal cells which are responsible for transferring of
molecules between serum and hepatocytes, scavenging of waste, secretion of cytokine and antigen
presentation. Pit cells are in charge of cytotoxic activity, while Kupffer cells scavenge foreign
material and secrete cytokines. Finally, hepatic stellate cells are in charge of maintaining
extracellular matrix, vitamin A synthesis, and retinoid deposition.
Developing cardiac mesoderm has an indispensable role during the hepatic cell fate phase
based on the studies done on mouse and chick embryos[27][28]. Fibroblast growth factor (FGF)
family is responsible for these inductive signals as FGF1 and FGF2 are capable of substituting
cardiac tissue at the Albumin kickoff which is known to be characteristic to hepatic cell fate[29].
FGF-induced (including Fgf1, Fgf2, Fg8, and Fg10 which are believed to have overlapping
functionality[30]) hepatic gene expression is regulated via mitogen-activated protein kinase
(MAPK) pathway in the cardiac mesoderm during the hepatogenesis knockoff phase[31]. FGF
signaling necessity is conserved throughout t evolution, as Xenopus, chick and Zebrafish embryos
exhibit the same requirements[32].
7

Cells going through a hepatocyte cell fate acquire a certain gene expression and
physiological profile during the embryonic and postnatal phases[33]. There is a complex network
of transcription factors in the hepatocyte gene expression regulation. The main players in this
network are HNF1a, HNF1β, FoxA2, HNF4a, HNF6, and LRH-1 [Nr5a2] working by occupying
each other’s promoters and thus form the regulatory circuity[34]. HNF1b, FoxA2, and HNF6 are
involved in controlling the hepatic gene expression kickoff during the specification and liver bud
formation[25]. HNF1a does not seem to have a big impact during embryogenesis which is thought
to be the HNF1β occupying the HNF1 binding sites initially but in the adulthood phase HNF1β
occupied promoter sequences were observed to be bound by HNF1a[35]. HNF4a does not seem to
affect hepatic speciation although subsequent differentiation is blocked[36]. In fetal hepatic
progenitors, the lack of HNF4a has a serious drawback[34] and preserving character in mature
ones are reported in the literature[37].
Even though there are many diseases associated with liver malignancy hepatocellular
carcinoma (HCC) is the most common one and is the ninth leading cause of cancer deaths in the
United States[38]. HCC is more prevalent in males than females by a ratio of 2.4 to 1 with a higher
strike rate for people with Eastern and Southern Asia, Middle and Western Africa, Melanesia and
Micronesia backgrounds[39]. Chronic liver disease, cirrhosis, viral hepatitis, and excessive
alcohol consumption are the leading risk factors of HCC[38]. Chronic medical conditions, namely
obesity (which is believed to increase the risk by 1.5 to 4 times) and diabetes mellitus (due to the
liver’s important role on glucose metabolism), also increase the risk of HCC. Treatment of HCC
patients is rather limited since the diagnosis are often done on patients with advanced HCC which
have gone through some liver damage already[38]. Among the treatments surgical techniques
such as resection[40], liver transplantation[41] as well as nonsurgical techniques such as
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transarterial chemoembolization[42], transartetial radiation[43], percutaneous local ablation[44]
and microwave ablation[45] exist.
Many of the known processes driving liver function have been identified through the study
of hepatoma cells which makes them favorable as a model for liver function. For example, several
key liver-specific transcriptional regulators have been identified using cultured liver-derived
cells[46]. More recently, hepatoma x fibroblast cell hybrids were used to identify candidate genes
possibly involved in driving both hepatic and fibroblast cell function using whole genome
approach. Of the genes identified as highly fibroblast-specific, two genes, Snai2 and Prrx1, were
shown to be able to reprogram cells hybrids to a fibroblast phenotype. Furthermore repression of
either of these genes in a fibroblast cell line resulted in dramatic reprograming of cells into a variety
of cell lineages, including chondrocyte and adipocyte cell phenotypes. Overexpression of these
genes in a hepatoma cell line resulted in repression of hepatoma genes and activation of fibroblast
genes.
1.5. Fibroblast as a Cell Model System
Within the body’s connective tissues, fibroblasts are the most common cell type. Their
main role is to secrete the components of the extracellular matrix (ECM)[47]. Fibroblasts are a
family of very heterogeneous multifunctional cells which have an important role in development
processes[48]. They are also instrumental in repairing tissue damage from inflammation and injury
since they can produce different types of paracrine immune modulators[49]. Fibroblasts are also
thought be involved in tumor development and progression as cancer and chronic inflammation
exhibit some analogies[50].
Fibroblasts are found in most of the tissues and organs in the body and is associated with
extracellular matrix (ECM) molecules[51]. Fibroblasts derive embryonically from mesenchymal
9

origin with a variety of phenotypic characteristics[52]. More recent findings suggest that the source
of fibroblasts after injury or disease can come from epithelial-mesenchymal transition (EMT) and
mesenchymal stem cells which are derived from bone marrow and tissue[53].
One of the most important functions of fibroblasts is the generation and control of ECM of
the tissue or organ. Fibroblasts do this function by synthesizing and secreting collagens,
proteoglycans, fibronectin, tenascin, laminin and fibronectin. They are very active cells and each
cell is thought to synthesize 3.5 million procollagen molecules per day[54]. Fibroblasts also
generate matrix metalloproteinases, their inhibitors, and tissue inhibitors of metalloproteinase that
regulate extracellular degradation. Another important function of fibroblasts is regulation of tissue
interstitial fluid volume as well as pressure through interaction of β1 integrin receptors[55]. The
last important function of fibroblasts is the involvement in wound healing and repair which
includes clot formation and platelet degranulation followed by releasing mediators to attract
relevant cells to the wound area[56]. It replaces the matrix with a more mature ECM and
subsequently heals the wounded site.
1.6. Twist-related Protein 1 (Twist1)
Twist1 was first identified in Drosophila as an indispensable gene for mesoderm formation
and differentiation into different distinct tissue types as well as dorsal-ventral patterning in the
early embryo development phase[57]–[60]. The name was given since the Drosophila embryos
lacking Twist1 gene died at the end of embryogenesis looking “twisted”[60]. The Twist1 gene
encodes a transcription factor that is comprised of a basic helix-loop-helix (bHLH) domain as well
as an amino-acid motif[61]–[63]. The important role of Twist1 in the development of mesoderm
has been established. For example, Twist1 gene mutations in human cause Saethre-Chotzen
syndrome which is an autosomal dominant inheritance disease[64]. Similar effects were observed
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in gene-ablation studies involving Twist1 null mice[65]. More recently, a crucial role Twist1 plays
in cancer metastasis has emerged in the literature[66]–[68].
Belonging to the bHLH family which is characterized by the formation of a domain
consisting basic amino acids sitting next to two amphipathic α-helices that are separated by an
inter-helical loop[61]. The α-helices moderate the interaction with another bHLH factor and cause
the production of a dimer that binds to Nde1 E-box which has an indispensable role for a variety
types of organogenesis[63]. There are three subfamilies within bHLH family. Class A proteins are
omnipresent among the mammalians. Class B proteins are specific to tissue expression and form
dimers with class A molecules in order to bind to E-boxes. The final class C subfamily do not form
dimers with other classes. Twist1 belongs to the family of class B[69].

Figure 4. Location of Twist1 gene in human. Taken from[70]

Human Twist1 gene has two exons and one intron and is mapped to 7p21.2[71] as shown
in Figure 4. The first exon contains an ATG site which is followed by 202 amino-acid residues
that are in turn followed by an untranslated portion (45-bp) in exon 1, 536-bp intron and another
untranslated portion in exon 2[57]. Human Twist1 molecular weight is approximately 21 kDa, and
has a theoretical isoelectric point of 9.6. This protein has more polar amino-acid residues near the
NH2 ends whereas more nonpolar residues at the COOH ends. Hence, NH2 terminus is more
hydrophilic.
11

Human Twist1 protein and mouse Twist1 protein are 96% identical with the bHLH domain
between residue109 to residue163 has exactly the same homology[72]. Molecular structure of human
Twist1 protein is shown Figure 5. Moreover, bHLH domains of Twist1 is mostly conserved among
many species such as human, mouse, frog, Drosophila, leech and Caenorhabditis elegans. 109Q –
T121 region of human Twist1 protein is the main region in charge of binding to DNA. Furthermore,
Loop-Helix II region also plays a role in the DNA binding process. Not only does Twist1 form
dimer in order to bind to DNA, it also interacts with MyoD which is responsible for muscle
differentiation. Hence, this interaction leads to suppression of muscle differentiation[73].

Figure 5. Molecular structure of human Twist1 protein. Taken from[57]

Twist box (also called WR motif) which is found between 20 and 55 amino acids from
COOH-terminal to bHLH area is protected among vertebrates. This region has 100% homology
among human (corresponding to between residue180 and residue202), mouse and Xenopus[57]. On
the contrary, a more historic species such as C. elegans does not contain a WR dipeptide. This WR
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domain is necessary for the transactivation of Twist1 and any genetic mutation in this area results
in Saethre-Chotzen syndrome for humans[74].
Aside from Twist1, there is also Twist2 protein. The Twist2 protein in humans has 160
amino-acid residues and it has only 68% identical homology-wise. However, the amino-acid
sequences in bHLH and Twist box domains are essentially identical and it is the reason for their
mutually redundant functions[57].
Being a major player in organogenesis, Twist1 is mostly expressed in tissues derived from
mesoderm. In Drosophilia, it has been shown that cellular blastoderm stage is the first phase
Twist1 is detected[75]. In the early gastrulation era, Twist1 expression is observed to be high in
the mesodermal layer of the embryos. Late gastrulation phase comes and Twist1 can be observed
in the cells of germ band mesodermal layer as well as anterior midgut primordium. In the later
stages, Twist1 expression weakens but can still be seen within the mesodermal layer of
somatopleura and splanchnopleura. After birth happens, it can be observed in adult mesenchymal
cells such as muscle stem cells[76][77]. It is worth mentioning that at all developmental stages,
Twist1 is localized in the nuclei since it is a nuclear protein.
As another important model, Twist1 is first observed at embryonic day 7.5 during mouse
embryogenesis in the anterior-lateral mesoderm underneath the head folds, inside the primitive
streak epiblast as well as in scattered cells in the amniotic cavity[77][78]. Afterwards, Twist1 is
observed sequentially in the metameric segments, the neural crest derived head mesenchyme, the
first aortic arches, the lateral mesoderm, the second, third and fourth branchial arches, the anterior
limb buds, and finally, the posterior limb buds[79]. Twist1 is likely to be expressed initially along
a dorsoventral gradient pattern until the headfold phase, followed by expression along the rostrocaudal axis of the embryos[57].
13

Unfortunately, dominant Twist1 expression areas during embryo development stages for
humans are not as developed as Drosophilia and mouse, although there have been reports in the
literature. Twist1 expression was strongly observed in the placenta. More specifically, in the fetal
region of the placenta which is unsurprisingly comes from the mesoderm[71]. Less strong
expression levels were observed in the adult heart and skeletal muscle. Even weaker signals were
seen in the kidney and pancreas whereas brain cells which are derived from ectoderm and lung
and liver cells which are derived from endoderm did not express any Twist1 signal. Considering
cell lines derived from human, WI-38 cells (fetal fibroblasts from lung), human peritoneal
mesothelial cells and endometrial fibroblasts as well as mesenchymal stem cells derived from bone
marrow showed Twist1 signals[80]. To summarize, Twist1, an indispensable gene for
organogenesis, is mostly expressed in the mesoderm-derived cells. After birth, it is mostly
expressed in adult stem cells.
Twist1 is a vital regulator of many biological processes. Required for the proper
development of mesenchyme derivatives, Twist1 executes a set of downstream target genes[81].
However, the exact molecular mechanism of Twist1’s role on mesenchymal tissue formation is
not developed[69].
One signaling Twist1 is involved is Fibroblast Growth Factor (FGF) signaling
pathway[82]. In Drosophilia Twist1 activates the expression of DFR1 and in C. elegans eg115[69]. As mentioned before, mutations in Twist1 causes Saethre-Chotzen syndrome which is
believed to be due to the necessity of Twist1 for FGF signaling during morphogenesis[83].
Apart from FGF signaling, Twist1 is also involved in Bone morphogenetic protein (BMP)
and probably Transforming Growth Factor-β (TGF-β) signaling[84]. As opposed to other bHLH
proteins, Twist1 has the ability to build functional homodimers (T/T) as well as heterodimers with
14

E12 (T/E). Homodimers and heterodimers have different actions and influence different gene sets’
expression. It is possible to pinpoint the ratio between these dimers by checking relative levels of
Twist1 and helix-loop-helix Id proteins as Twist1 tends to form heterodimers when Id proteins are
absent and homodimers when present[84]. Id proteins are a different class of HLH and compete
with Twist1 by forming dimers with E12 and inhibiting heterodimer formation by Twist1s[85]. In
light of this knowledge, in the areas where Twist1 and Id1 are expressed together such as fronts of
cranial structures, genes regulated by T/T dimers are expressed. On the flip side, T/E regulated
genes are expressed in mid-sutures and it has been shown to suppress BMP signaling[82][86]. As
BMP signaling activates Id expression, it leads to more homodimer (T/T) formation. This makes
up a positive feedback loop that is believed to cause the early closure of the sutures[57]. Similar
effect takes place in the limb bud for the case of FGF signaling[87]. Twist1 is also found to be
indispensable for Bmp4 expression in the apical ectoderm[87].
An opposite feedback loop, namely negative feedback, happens in Tumor necrosis factor
(TNFα) which activates both proapoptotic and antiapoptotic pathways. In order to prevent
apoptosis, TNFα activated NF-κB upregulates Twist1 as well as Twist2. In response to this, Twist1
and Twist2 reacts with a subunit of NF-κB to inhibit cytokine genes expression[57]. This negative
feedback loop is thought to have a role in impeding overactivation of cytokine expression[88].
Another very important role Twist1 plays besides the role in organogenesis is the
expression of in aggressive tumors in a variety of cancer types such as breast cancer[66],
hepatocellular carcinoma[89], prostate cancer[90], gastric cancer[91], esophageal squamous cell
carcinoma[92], bladder cancer[93] and pancreatic cancer[94]. Twist1 has a presence in cancer
initiation, progression as well as metastasis[57]. Amino acid sequences of well characterized
species are shown in Figure 6.
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Figure 6. Amino acid sequences among human (H), mouse (M), xenopus (X), Drosophilia
(D), leech (L) and C. Elegans (C). Taken from[57]
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Most well-known effects of Twist1 in cancer is the promotion of cancer cell (epithelialmesenchymal transition) EMT and metastasis. Metastasis has many steps including EMT, local
invasion, intravasation, transportation, extravasation, proliferation at another site and production
of overt metastatic lesions[95]. Just as it does for development, Twist1 exhibits a similar behavior
by supporting the cells to undergo EMT and move to form secondary tumor sites[96].
Although Twist1 plays an important role in many types of cancers, the way it expresses,
functions and the molecular mechanisms affected in this process vary for each type of cancer. Due
to the topic of the thesis, I will cover only the hepatocellular carcinoma (HCC). HCC is a metastatic
tumor characterized by rapid growth[57]. It has been shown that Twist1 overexpression has a
positive correlation with HCC metastasis and a negative correlation with E-cadherin
expression[89]. The demonstration of higher levels of Twist1 and lower levels of E-cadherin
corresponding to higher metastatic capability implies that Twist1 inhibits E-cadherin expression
and activates EMT alterations[89]. Upregulation of vascular endothelial growth factor (VEGF)
and N-cadherin by Twist1 in HCC points to Twist1’s role in HCC angiogenesis[97]. Another study
demonstrated the increased mobility effect of overexpression of Twist1 on HCC cells[98]. In a
study[99] involving Twist1 with two other major EMT regulators (Snail and Slug) the synergistic
effect of Twist1 and Snail in enhancing HCC metastasis was demonstrated. Co-expression of Snail
and Twist1 decreased E-cadherin and deteriorated prognosis significantly compared to Twist1
expression alone whereas Slug expression was not significant. Further verification comes from a
study demonstrating Twist1’s effect on increased motility, invasiveness via inhibiting E-cadherin
expression and upregulation of N-cadherin[100].
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1.7. Epithelial-Mesenchymal Transition (EMT) and Regulation of EMT
Epithelial tissue is comprised of tightly-packed epithelial cells and is useful to protect the
body from outside hazards as this tight packing of cells provide the required structural robustness
due to strong cell-cell and cell-matrix interactions[101]. As opposed to epithelial tissue
mesenchymal tissue is a loose connective tissue that exists in early embryo. Composed of
fibroblast-like shaped cells, mesenchymal cells are highly mobile thanks to their loose
interactions[102]. Being undifferentiated, mesenchymal cells have stem cell properties.
In the beginning phase of an organism’s development, there is only a single cell which is
the fertilized egg. As time passes, the multiplied cells from the egg have to differentiate into three
separate tissue types which are endoderm, ectoderm and mesoderm. The differentiation process
was once believed to end after a certain time passes[101] but more recent evidence showed
differentiation continues in response to physical damage and stress[103][104]. Epithelialmesenchymal transition (EMT) is a biological process of epithelial cells gaining mesenchymal
properties via physical and biochemical changes, and is the mechanism for cellular diversity. As a
result of this process, epithelial cells lose their rigid architecture and become mobile, apoptosis
resistant cells just like mesenchymal cells. Figure 7 shows the process of EMT[105]. After the
transition, these cells move around the body to perform tasks such as tissue reconstruction and
repair[106]. After migrating to the necessary part of the body, these cells undergo a reverse
transition called mesenchymal-epithelial transition (MET) to become rigid, immobile cells once
again[107].
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Figure 7. Functional transition from epithelial to mesenchymal phenotype. Taken
from[105]

Besides being a key player in for embryonic development, EMT also plays an important
role in tumorigenesis since it promotes invasive and metastatic properties of epithelial cancer cells
according to animal studies conducted[108]. Some signaling pathways involved in EMT during
embryonic development are present in EMT during carcinogenesis[101]. It was suggested that
these epithelial cells from the primary tumors become motile through the process of EMT and
move away from the primary tumor area and cause secondary tumors at distant places where they
have metastasized. They again become rigid and immotile once again through the process of
MET[106]. This behavior has been observed for breast, ovarian, colon, and esophageal
cancer[109].
It is important to state there is not only one type of EMT and each one occurs for a specific
type of requirement. Type I EMT is linked to implantation, embryo formation, and organ
development and thus pivotal in cell type differentiation. It is possible to go back to form epithelial
cells through the process of MET. Type II EMT, on the other hand, occurs in reaction to an
inflammation and stops once the inflammation is reduced. Hence, type II EMT occurs during tissue
repair and damage healing. Type III EMT is found in solid tumors and makes the epithelial cells
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invasive, leading to metastasis. A schematic showing all three types of EMT is illustrated in Figure
8[105].

Figure 8. Three different types of EMT. Taken from[105]

During EMT, gene expression levels are altered as down-regulation of epithelial markers
such as E-cadherin and up-regulation of mesenchymal markers such as vimentin and N-cadherin
occurs[104]. The most important marker for EMT is the E-cadherin which plays a significant role
in cell-cell adhesion[107]. Since E-cadherin is important for epithelial cells to be immotile,
reduction of E-cadherin levels leads to increase in invasiveness and change of adenoma to
carcinoma. Hence, expression of E-cadherin is inversely correlated with tumor grade and
stage[110][111]. E-cadherin levels are regulated both at the genomic and transcriptional level. It
is possible to reduce activation of E-cadherin gene CDH1 by mutations as well as loss of CDH1
heterozygosity and hyper-methylation of CDH1 promoter[107]. Activation of EMT-inducing
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pathways is possible through the use of growth factors such as fibroblast growth factor, epidermal
growth factor, hepatocyte growth factor and transforming growth factor (TGF-β). The last factor
is instrumental in many processes in the body including regulating growth, as well as
differentiation and migration of cells during cancer progression, and metastasis[112].
The crucial players of EMT pathways are also E-cadherin repressors. One of them is Snail
which is a zinc finger DNA binding protein present in normal growth as well as tumorigenesis and
has been shown to be an important mediator of EMT in human and mouse invasive carcinoma
cells[112]. Another important EMT inducer is Twist, a helix-loop-helix transcription factor. Twist
inhibits E-cadherin via binding to E box motifs which are also directed by Snail and overexpression
of both inducers has been shown to be linked to loss of E-cadherin as well as increase in N-cadherin
in human gastric cancer[113]. Many EMT-inducing transcription factors act synergistically. For
example, in human cells Twist1 activates Snail2 by directly binding to its promoter area and these
two transcription factors are believed to be conserved through evolution and play an important role
during embryogenesis and tumor metastasis[114].
Other studies on EMT focused on the effect of epigenetic alterations on up-regulation of
epithelial genes and down-regulation of mesenchymal genes during EMT[112]. TGF-β supports
the epigenetic control of EMT by inducing a DNA methyltransferase, namely DNMT1. It also
reduces the heterochromatic marker, di-methylation of Lys9, and increases euchromatin
marker[108]. Snail expression, in various types of carcinoma, is related to the E-cadherin promoter
hyper-methylation by binding to the promoter region. Afterwards, Snail uses a complex including
histone deacetyltransferases 1 and 2. Using this complex results in histone H3/H4 acetylation and
an increase in histone H3 methylation that in turn induces heterochromatic structure and restrains
E-cadherin expression[112].
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As an environmental factor hypoxia, defined as pressure of O2 levels being less than 10
mm Hg, is correlated with normal development and tumor progression[101]. Low oxygen
environment up-regulates hypoxia inducible factor (HIF-1) which interferes with the hypoxic
response by producing a transcription factor that activates transcription of target genes[104].
Hypoxia conditions up-regulate Snail and Twist, possibly through TGF-β stimulation[108] by
inducing Snail and Twist expression which reduces the expression of E-cadherin.
1.8. Project Overview and Goals of the Study
The most important roles Twist1 plays are involvement in organogenesis and the
expression of aggressive tumors in a variety of cancer types including hepatocellular carcinoma.
Besides Twist1, Snai2 is another EMT regulator according to previous studies[99]. Previous
studies showed that Snai2 overexpression in hepatoma cells (Fg14) activated expression of
fibroblast specific genes[115]. Moreover, Snai2 overexpression resulted in repression of liver
specific genes. This thesis addresses whether Twist1 has a similar effect as Snai2. More
specifically, the objective of this work is to determine how Twist1 transfection of hepatoma cells
(Fg14) affects fibroblast specific and hepatoma specific genes.
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Chapter 2
Materials and Methods
2.1. Cell Culture
All cells were stored in a medium that contains 1:1 Ham’s F12/Dulbecco’s modified
Eagle’s medium (FDV) which consists of 10% fetal bovine serum (FBS) (GIBCO BRL) and 5
µg/100 ml penicillin-streptomycin (GIBCO) at a temperature of 37° C with 5% humidity CO2
water-jacketed incubator. FG14 cells were derived from the parental cell line H4IIEC3 cells,
isolated from a rat tumor by Weiss and colleagues. RAT2 cells are a thymidine kinase negative
variant of the rat fibroblast cell line RAT1 and were obtained from American Tissue Type
Collection (ATCC).
Commercially available Lipofectame kit from Invitrogen was used to transfect the cells
with candidate genes. Briefly, DNA was mixed with a liposome reagent, trapping the DNA inside
the liposomes and allowing liposomes to fuse with cell membranes to release the DNA into the
cells. Expression vectors containing candidate gene TWIST1 was purchased from Origene, Inc.
Six-well cell culture plates were used for the transfection process of candidate genes. Specifically,
0.5 ml of FDV media without penicillin and streptomycin (Pen/Strep) was added to a microcentrifuge tube., DNA (1 µg/µl) was added, mixed then and 5 µl Lipofectamine Plus reagent was
added to the mixtures and mixed gently for five minutes at room temperature. Finally, 5 µl of
Lipofectamine LTX reagent was added to the mixture and was mixed gently by pipetting and
incubated for half an hour at room temperature.
Cells to be transfected were introduced in a 6-well format the day before transfection. The
transfection mixture that was prepared in the microfuge tubes before was added in the wells of the
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plates and incubated at 37°C with 5% CO2 for 6 to 8 hours while rocked. Afterwards, medium was
substituted with FDV containing 10% fetal bovine serum, penicillin and streptomycin and
incubated for 2 days at 37°C in 5% CO2 environment. Cells were split into various dilutions (1:20,
1:10 and 1:5 dilutions) in complete medium plus 500 µg /ml G418 and was incubated for 2 to 3
weeks. After this process, G418 resistant clones were either pooled (10 to 50 clones per pool) or
picked individually then expanded into larger plates until the cells could be lysed and ready for
RNA extraction.
To determine the transfection efficiency, cells were also transfected with a Green
Fluorescent Protein (GFP) expression plasmid. Based on GFP positive cells after 48 hours, we
estimated between 4 and 6% transfection was achieved Furthermore, a DNA free control plate
was used a negative control to make sure no G418–resistant cells were present in the cell line being
transfected.
2.2. RNA Isolation
RNA extraction from confluent cell lines was performed using an RNeasy Mini Kit from
Qiagen, with a DNase-I step modification. Briefly, the medium was removed, and the denaturing
reagent guanidine isothiocyanate (GITC) and β- mercaptoethanol (RLT buffer) were used to lyse
the cells. Following this procedure, lysed cells were placed in a collection tube for homogenization
by centrifugation through a QiaShreddr (Qiagen) mini-column. One volume of ethanol was added
followed by application of an RNeasy column in a collection tube. RW1 buffer was used to wash
the resin filter and digested with DNase I for 15 min at room temperature. The filter was washed
with RW1 again first and RPE buffer second followed by quick centrifugation after each treatment.
RNA was then eluted from resin filter by addition of 40 µl to the column followed by centrifugation
at 10,000 x g for 1 minute. Extracted RNA samples were transferred to microfuge tubes and stored
24

at -70° C. Nano-drop spectroscopy at 260 and 280 nm was used to determine concentration and
purity of the purified RNA.
2.3. cDNA Synthesis
A mature, fully spliced, messenger RNA was used to acquire complementary DNA with
the help of reverse transcriptase enzyme. In this procedure, Poly-T oligonucleotides anneal to polyA tails of the RNA and addition of it creates the required complimentary DNA strand which was
generated by first digesting the RNA strand using Ribonuclease H. Afterwards, complementary
strand synthesis yields the double stranded DNA.
To produce cDNA from previously purified RNA, MasterAmp High Fidelity RT-PCR kit from
Applied Biosystems was used. Reaction mixtures contained 10X RT Buffer, 25uM dNTP Mix,
10uM RT Random Primers, MultiScribe, sterile nuclease free water and 1 µg RNA in a final 20
µl volume. The RNA mixture was incubated at 37° C for 30 minutes. The settings in the Bio-rad
Thermal Cycler used to synthesize cDNA are: 25°C for 10 min, followed by 37°C for 2 hours,
85°C for 5 min, then 4°C until final products are transferred to a microfuge tube and stored at 20°C. Afterwards, the stored cDNA tubes were diluted to the previously determined concentrations
to be used for quantitative PCR.
2.4. Primer Design
Primer design was done using software provided by NCBI which is programmed to
optimize and identify primer pairs that hybridize to single gene targets at appropriate temperatures
(between 55 and 65°C in our case) and produce short amplicons when using qPCR. The suitable
primers were purchased from Integrated DNA Technologies Inc. Three primers sets were designed
for each gene to be tested. The best performing primer set (producing optimal amplification with
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lowest background signal for both cells of interest) namely the parental hepatoma cells and
fibroblasts cells were used for subsequent experiments. Genes whose expression was known to be
significant in hepatic and fibroblast function based on the literature was monitored using qPCR.
Primer pairs in this study and their predicted melting and annealing temperatures are given in the
Tables 1 and 2.
Table 1. Primers used in the quantitative Polymerase Chain Reaction (qPCR), primer sequences,
melting temperature and annealing temperature of primers for the parental hepatoma cells.
Primer

Primer Sequence

Hnf1

F-5' CCATTCTGAAAGAGCTGGAGAAC3'
R-5' AGGTACGACTTGACCATCTTTGC3'
F-5' TGGCAGAACTCCATCCGTCATTC3'
R-5' AACTGGATCTGCTCGATCATCTG3'
F-5’ CAGTGGCTCTAAGCACAGTAA 3’
R-5’ CAGTGTGGTGGAACAGATAAGA 3’
F-5’ CCTATACCGGGAGCTGGTCCAT 3’
R-5’ TTGCGAGTGTCACCCTTGCT 3’
F- 5’ CATCCTGAACCGTCTGTGTG 3’
R-5’ TTTCCACCAAAGACCCACTA 3
F- 5’ AACACAATTGCCGCCTTCTCACAG
3’
R-5’ GTGCAATGGAATGACCAAGTGCCT
3’
F-5’ AAGGAGACAAGGTGAAGGCACACT
3’
R-5’ AAGAACATGCCGTTGTGGATGCTC
3’
F- 5’ CGCTATGCGGCCCTTCTTT 3’
R-5’ CGTGAAAGATCTTGGGCAACT 3’
F-5’ TGATTCTACCCACGGCAAGTT 3’
R-5’ TGATGGGTTTCCCATTGATGA 3’
F-5’ CATCAGACACCCTGAGATGAAA 3’
R-5’ GGTCCACCAAAGTAGTCCAAA 3’

Hnf4
Hnf6
Serpina1
Alb
rKng1(1)

rFgb1 (4)

rPck1 (2)
Gapdh
rCreg1 (3)
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Melting
Temperature
57.1
55.6
56.6
56.5
54.5
54.3
60.3
59.5
55.7
55.8
60.2
60.2

Annealing
Temperature
60

60.3
59.9

64

58.3
57.5
56.5
54.2
54.4
54.8

60

60
60
64
60
64

60
60

Table 2. Primers used in the quantitative Polymerase Chain Reaction (qPCR), primer sequences,
melting temperature and annealing temperature of primers for the parental fibroblast cells.
Primer

Primer Sequence

Prrx1

F-5' GAACCGAAGCTGGGAGAAA 3'
R-5' AGGAGAGAGAGAGAGAGAGAGA 3'
F-5' CTGGATACTCCTCATCTTTGGG 3'
R-5' CTCTTCGTCACTAATGGGACTT 3'
F-5' GCTGGTGCATTACAGAGAGAA 3'
R-5' GTGTGTTTCACGCACAGATAAG 3'
F-5' TCGCTGAACGAGGCATTT 3'
R-5' GCCAGTTTGAGGGTCTGAAT 3'
F-5' CTGAAGGATCGCAAAGAGGATG 3'
R-5' CGTTGAGTTGTTCCAGGGTAAA 3'
F-5' CAGCCAAGGACCAACTACAA 3'
R-5' TGCCAACTCAGCCACTT 3'
F-5' CTAGAGGCTAGAGGGAGAACTT 3'
R-5' GACAGAGAGACAGAGACAGAGA 3'
F-5' ACTGGTACATCAGCCCAAAC 3'
R-5' GGAACCTTCGCTTCCATACTC 3'
F-5' GGGACGAGACTTTGCTATCTTC 3'
R-5' GATGGGCACTGATGAATCTAGG 3'

Snai2
C-Fos
Twist
Shox2
Sppl
Bmp3
Col1a1
Sema3a

Melting
Temperature
54.9
54.9
54.5
54.1
54.8
54.3
54.8
55.1
55.6
55.2
55.0
54.8
54.9
54.8
55.0
55.3
55.1
55.1

Annealing
Temperature
60
60
60
60
60
60
60
60
60

2.5. Quantitative-Polymerase Chain Reaction (qPCR)
All the cDNA samples were diluted to a concentration of 5 ng/µl for all the samples. A
final volume of 20 µl of reaction mixture contained 2 µl of cDNA template at a concentration of 5
ng/µl, 6.75 µl of sterile nuclease free water, 10 µl of Fast SYBR® Green Master Mix purchased
from Applied Biosystem and 1.25 µl of gene specific primer at a 0.5 µM concentration (IDTDNA).
To quantify the expression of mRNA level, Applied Biosystem thermocycler was used. The first
step was done at 95° C for 3 sec which is followed by an annealing step happening at 5°C above
the primer melting temperature for 30 sec for 40 cycles. A final melt curve step was performed at
95°C for 15 sec, followed by going down to 60°C for 1 minute and a final step at 95°C for 15 sec.
The control used for qPCR is comprised of 8.75 µl of sterile nuclease free water, 10 µl of Fast
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SYBR® Green Master Mix and 1.25 µl of gene specific primer at a concentration of 0.5 µM
(IDTDNA). The reference gene used to test the cDNA quality was Gapdh. Duplicate assay was
performed for each cell line and reactions were repeated three times for reproducibility purposes.
Raw threshold (Ct) values were calculated by taking the average after the amplification for
each of the cell lines. The amplified target genes in each hepatoma and fibroblast cells were
normalized to Gapdh for the respective Ct‐value, generating a delta-Ct value (ΔCt). Fold
differences in gene expression were determined with a delta delta‐Ct (ΔΔCt) calculation. The ΔCt
of the control cell line (Fg14) was subtracted from the hepatoma variant ΔCt value, generating a
ΔΔCt value. Using a log base 2 scale, the calculated difference was placed into the ΔΔCt equation:
2(ΔCt (sample – experimental) − (ΔCt Control).
2.6. Statistical Analysis
Statistical significance was determined using student t-test assuming unequal variance.
Significance value was accepted at p < 0.05 level.
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Chapter 3
Results
We used hepatoma cell line Fg14 as a model to study the role of candidate gene Twist1 in
the regulation of fibroblasts-specific gene expression. The results can be regarded as an extension
of past studies from our laboratory which originally identified candidate master regulatory genes
in a genome-wide screening of gene expression in hepatoma x fibroblast cell hybrids that could
remodel cell hybrids to become more fibroblastic in nature[46]. Previous studies showed that Snai2
overexpression in hepatoma cells (Fg14) activated expression of fibroblast specific genes[115].
Moreover, Snai2 overexpression resulted in repression of liver specific genes. This thesis
addresses whether Twist1 has a similar effect as Snai2. More specifically, the objective of this
work is to determine whether Twist1 overexpression in hepatoma cells (Fg14) can reprogram these
hepatoma cells to become more fibroblast-like. To that end, we monitored fibroblast specific and
hepatoma specific gene expression in response to Twist1 overexpression.
Expression cassettes containing the mouse Twist1gene in a neo plasmid vector was
transfected into the Fg14 cells and G418 selection applied. There was only one pool and three
total clones. A parallel non-transfected negative control was included which, as expected, resulted
in no G418 resistant clones. G418 resistant clones were picked individually or pooled and
expanded into 100mm cell culture dishes. Following this procedure, RNA was extracted and used
to generate complimentary DNA (cDNA) that was later used in the qPCR reactions to monitor
expression of target genes.
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3.1. Expression Comparison of Fibroblast and Hepatoma-specific Genes
We first compared gene expression profiles of key liver-specific and fibroblast -specific
genes between the RAT1 fibroblasts cells and the Fg14 cells using rat-specific primers. For
hepatoma cells, we measured expression of genes encoding transcription factors known to be
important in driving the liver phenotype. These included transactivator genes Hnf4, Hnf1, Hnf6 as
well as Creg1, a gene recently identified in our laboratory as being important for liver function.
Results show that of these genes are highly liver-specific, with levels 100-1000 fold higher in the
hepatoma cells compared to those in the RAT2 fibroblast cell line (Fig. 9). We next measured
expression of a panel of fibroblast specific genes known to be important in driving the fibroblast
phenotype. These included Prrx1, Snai2, C-fos, Shox2, Sppl, Col1a, and Sema3a and the gene of
interest, Twist1. As expected, result show that Fg14 cell expression of these genes is 2 to 3 orders
of magnitude lower than in the RAT1 fibroblasts (Fig 10).
3.2. Twist1 Overexpression in Fg14-transfected Cells
As shown above, Twist1 is expressed at levels >100 fold lower than those in the RAT2
fibroblasts.

We next asked whether the transfected mouse Twist1 gene was expressed in

transfected Fg14 cells. To do this, mouse-specific primers were used, as the rat primers failed to
cross-hybridize to the mouse cDNA sequences (results not shown). Results from RT-qPCR
analysis show that mouse Twist1 was successfully over-expressed in pooled Fg14 transfectants as
well as two (clones 4 and 8) of the three individual clones compared to the non-transfected Fg14
cells (Fig. 11). A third clone (clone 6) showed no detectable expression of the Twists1 transgene,
and therefore serves as a negative control for non-specific effects.
As mentioned above, both the pooled clones well as the two out of the three individual
clones tested expressed the introduced Twist1 gene at levels >2500 fold higher than the signal in
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the Fg14 cells (Fig. 11) . It is important to mention that since the used primers are mouse-specific,
background signals in the rat-derived Fg14 cells could either be due to cross-hybridization to rat
sequences or spurious hybridizations to other sequences.
3.3. Twist1 Overexpression – Activation of downstream hepatoma-specific genes
The next set of experiments were done to address the question of whether Twist1
overexpression in hepatoma cells (Fg14) could affect expression of downstream hepatoma-specific
genes. Regulation of downstream genes in distinct cell types depends largely upon transcriptional
control. It is known that regulation and/or activation of liver specific downstream genes
necessitates binding of hepatocyte nuclear factors and co-activators to promoter regions. Due to
the established features of Twist1 and its fibroblast specificity, we asked if it could alter liverspecific downstream genes (which would suggest reprogramming of these cells). Expression of 10
different key liver markers was monitored. In each case, expression profiles were compared
between the non-transfected Fg14 cells and the Twist1-transfected cells (pools and three clones).
All values obtained from the thermal cycle were controlled for Gapdh expression for each
cell line tested. All cells lines showed Gapdh levels with 3 cycles and expression results obtained
for each gene was normalized to these differences in Gapdh levels. This assumes that Gapdh levels
are unaffected by introduction of the transgene and instead reflects technical variation in RNA
isolation, cDNA production, or assay preparation.
For some of the hepatoma-specific genes including Hnf1, Creg1, Hnf3, and Serpina1 (see
Figs 12, 17, 18 and 19, respectively), levels were within 3-fold of the non-transfected Fg14 cells.
For other genes including Hnf4, Alb, Pck1, Kng1 and Fgb (see Figs. 13, 15, 16, 20 and 21,
respectively) an unexpected increase in expression was observed in clones compared to the Fg14
parental line. For example, both Alb and HNF4 showed 5-15 fold activation in the transfected
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clones compared to the pooled transfectants. Clone 6 produced the highest levels, despite the fact
that we were unable to detect expression of the introduced transgene in this clone (see Fig. 11),
leading us to conclude that the levels detected for these genes were independent of Twist1
expression.
Of the 10 genes tested, only Hnf6 showed a possible effect on gene expression due to the
in introduction of the mouse Twists1. The pooled transfectants showed a 6-fold increase, with
clones 4 and 8 having a more modest 2-fold increase compared to either non-transfected on nonexpressing Fg14 cells, Therefore, little if any effect on liver-specific genes expression was
observed by overexpression of the mouse Twist1 gene.
3.4. Effect of Twist1 overexpression on fibroblast-specific gene expression
In the next section, we tried to answer the question of whether Twist1 overexpression in
hepatoma cells (Fg14) could affect expression of downstream fibroblast genes. As described above
fibroblast-specific genes expressed at levels more than 100-fold below those in the Fg14 hepatoma
cell line (Fig10). Therefore, Pooled Fg14-Twist1 cells were tested for fibroblast-specific gene
expression using qPCR. Expression of 7 different key fibroblast markers was monitored, in each
case, expression profiles were compared between the non-transfected Fg14 cells and the Twist1transfected cells (pools and three clones).
All values obtained from the thermal cycle were controlled for Gapdh expression for each
cell line tested. All cells lines showed Gapdh levels with 3 cycles of each other, results obtained
for expression of each gene was normalized to these differences in Gapdh levels. This assumes
that Gapdh levels are unaffected by introduction of the transgene and instead reflects technical
variation in RNA isolation, cDNA production, or assay preparation.
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For some of the fibroblast-specific genes including Snai2, C-fos, Col1a1, and Sema3a (see
Figs. 23, 24, 27, and 28) expression levels were 20 to 90% lower than that of the non-transfected
Fg14 cells with an unexpected increase in expression for Sema3a clone 4. Additionally, Snai2
expression levels in Fg pool is comparable to non-transfected Fg14 cells expression levels. For the
genes Prrx1, Shox2, and Sppl (see Figs. 22, 25, and 26) expression levels were 20 to 95% lower
than non-transfected Fg14 cells with no expression for some cases, specifically, Prrx pool, Shox2
clone 8, Sppl pool and clone 6.
Of the 7 genes tested, only Prrx1 showed significant expression levels for clone which is
20 to 90 fold compared to non-transfected Fg14 cells while the pool has expressed levels of half
the intensity.
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Figure 9. Comparative expression of key liver-specific genes in hepatoma cells vs fibroblast
cells. Rat-specific primers were used to monitor expression of known liver-specific genes in the
Fg14 rat hepatoma cell lines and RAT1 fibroblasts cells. cDNA derived from isolated mRNA
was monitored by qPCR analysis. The cycle numbers shown are compared to those obtained
from the RAT1 cells and normalized to Gapdh levels using the ΔΔCT method for each cell line.
The experiments were repeated at least 3 times, with triplicate reactions sets for each.
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Figure 10. Comparative expression of key fibroblast genes in hepatoma cells vs fibroblast
cells. Rat-specific primers were used to monitor expression of known liver-specific genes in the
Fg14 rat hepatoma cell lines and RAT2 fibroblasts cells. cDNA derived from isolated mRNA
was monitored by qPCR analysis. The cycle numbers shown are compared to those obtained
from the Fg14 cells and normalized to Gapdh levels using the ΔΔCT method for each cell line.
The experiments were repeated at least 3 times, with triplicate reactions sets for each.
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Figure 11. Twist1 overexpression in transfected Fg14 rat hepatoma cells. Mouse-specific
primers were used to monitor over-expression of the introduced mouse Twist1 gene in the Fg14
rat hepatoma cell line. Fg14 cells were stably transfected with a mouse Twist1 expression
plasmid, and G418-resistant clones pooled or selected individually. Cellular mRNA was isolated,
converted to cDNA, and monitored by qPCR analysis. The cycle numbers shown are compared
to those obtained from the Fg14 cells and normalized to Gapdh levels using the ΔΔCT method
for each cell line. The experiments were repeated at least 3 times, with triplicate reactions set for
each trial.
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Figure 12. mTwist1 does not affect Hnf1a expression in Fg14 cells. Rat-specific Hnf1a
primers were used to monitor Hnf1a expression in transfected cell using qPCR analysis. The
cycle numbers shown are compared to those obtained from the Fg14 cells and normalized to
Gapdh levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3
times, with triplicate reactions set for each trial.
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Figure 13. mTwist1 activates expression of Hnf4 in Fg14 cells. Rat-specific Hnf4 primers
were used to monitor Hnf4 expression in transfected cell using qPCR analysis. The cycle
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh
levels using the ΔΔCT method for each cell line. The experiments were performed in triplicate.
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Figure 14. mTwist1 activates expression of Hnf6 in Fg14 cells. Rat-specific Hnf6 primers
were used to monitor Hnfn6 expression in transfected cell using qPCR analysis. The cycle
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh
levels using the ΔΔCT method for each cell line. The experiments were performed in triplicate.
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Figure 15. mTwist1 effects on Alb expression in Fg14 cells. Rat-specific Alb primers were
used to monitor Alb expression in transfected cell using qPCR analysis. The cycle numbers
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with
triplicate reactions set for each trial.

40

Figure 16. mTwist1 effects on Pck1 expression in Fg14 cells. Rat-specific Pck1 primers were
used to monitor Pck1 expression in transfected cell using qPCR analysis. The cycle numbers
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with
triplicate reactions set for each trial.

41

Figure 17. mTwist1 effects on Creg1 expression in Fg14 cells. Rat-specific Creg1 primers
were used to monitor Creg1 expression in transfected cell using qPCR analysis. The cycle
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh
levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 times,
with triplicate reactions set for each trial.
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Figure 18. mTwist1 effects on Hnf3 expression in Fg14 cells. Rat-specific Hnf3 primers were
used to monitor Hnf3 expression in transfected cell using qPCR analysis. The cycle numbers
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with
triplicate reactions set for each trial.

43

Figure 19. mTwist1 effects on Serpina1 expression in Fg14 cells. Rat-specific Serpina1
primers were used to monitor Serpina1 expression in transfected cell using qPCR analysis. The
cycle numbers shown are compared to those obtained from the Fg14 cells and normalized to
Gapdh levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3
times, with triplicate reactions set for each trial.
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Figure 20. mTwist1 effects on Kng1 expression in Fg14 cells. Rat-specific Kng1 primers were
used to monitor Kng1 expression in transfected cell using qPCR analysis. The cycle numbers
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with
triplicate reactions set for each trial.
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Figure 21. mTwist1 effects on Fgb1 expression in Fg14 cells. Rat-specific Fgb1 primers were
used to monitor Fgb1 expression in transfected cell using qPCR analysis. The cycle numbers
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with
triplicate reactions set for each trial.
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Figure 22. mTwist1 effects on Prrx1 expression in Fg14 cells. Rat-specific Prrx1 primers
were used to monitor Prrx11 expression in transfected cell using qPCR analysis. The cycle
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh
levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 times,
with triplicate reactions set for each trial.
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Figure 23. mTwist1 effects on Snai2 expression in Fg14 cells. Rat-specific Snai2 primers
were used to monitor Snai2 expression in transfected cell using qPCR analysis. The cycle
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh
levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 times,
with triplicate reactions set for each trial.
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Figure 24. mTwist1 effects on C-fos expression in Fg14 cells. Rat-specific C-fos primers were
used to monitor C-fos expression in transfected cell using qPCR analysis. The cycle numbers
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with
triplicate reactions set for each trial.
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Figure 25. mTwist1 effects on Shox2 expression in Fg14 cells. Rat-specific Shox2 primers
were used to monitor Shox2 expression in transfected cell using qPCR analysis. The cycle
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh
levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 times,
with triplicate reactions set for each trial.
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Figure 26. mTwist1 effects on Spp1 expression in Fg14 cells. Rat-specific Spp1 primers were
used to monitor Spp1 expression in transfected cell using qPCR analysis. The cycle numbers
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with
triplicate reactions set for each trial.
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Figure 27. mTwist1 effects on Cola1a expression in Fg14 cells. Rat-specific Cola1a primers
were used to monitor Cola1a expression in transfected cell using qPCR analysis. The cycle
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh
levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 times,
with triplicate reactions set for each trial.
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Figure 28. mTwist1 effects on Sema3a expression in Fg14 cells. Rat-specific Sema3a primers
were used to monitor Sema3a expression in transfected cell using qPCR analysis. The cycle
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh
levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 times,
with triplicate reactions set for each trial.
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Chapter 4
Discussion and Future Directions
Transcription factors (TFs) have a very important role in activation of genes within a
genome to regulate development in mammalian cells. As described in the literature many control
mechanisms, namely histone modification, chromatin regulation, transcriptional control, posttranscriptional regulation and cell-cell contact, regulate gene expression in fibroblast cells[116].
Promoter-proximal elements and enhancers initiate transcriptional activity where transcription
factors bind[117]. Fibroblast-lineage TFs bind to regulatory regions of certain genes in a
synergistic fashion that leads to activation of these genes to form fibroblast identity in all distinct
tissues in complex organisms.
Fibroblast-specific gene expression was studied in our laboratory using cell hybrids as
model system combined with whole genome microarrays. The genes were identified by comparing
whole genome transcriptome microarray data of hepatoma cells and hepatoma x fibroblast hybrid
cells along with parental fibroblast cells by observing the fold differences in expression. The
experiments identified potential master regulators of fibroblast cell fate (fibroblast-specific TFs),
and their putative regulatory role in fibroblast differentiation. Among the identified genes are
transcription factors (e.g. Prrx1/Pmx, Slug, Snai2, Shox2, CFOS, Twistl, Hox-d10, and Msxl) as
well as fibroblast-specific downstream such as Sema3a, (cell signaling) Sppl, Bmp3 (cell
differentiation), and Collal (structural organization).
Among the fibroblast-specific candidate genes identified that have putative roles in the
maintenance of the fibroblast phenotype were transcription factors Snai2 and Twist1. A previous
study from our laboratory found out Snai2 was highly expressed in fibroblasts, silent in hepatoma
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cells, and repressed in hepatoma x fibroblasts cell hybrids. Moreover, forced over-expression of
these genes in the hybrid cells leads to activation of fibroblast gene expression and resulting
fibroblast-like morphology. We asked the question of whether a similar effect could be observed
for Twist1. The goal of this study was to determine the ability of a fibroblast-lineage specific TF
to remodel hepatoma cells.
4.1. Reprogramming the gene expression profile of hepatoma cells by Twist1 overexpression
In this study, we extended the results of a previous study from our lab which suggested that
overexpression of Prrx1 and Snai2 genes via introduction of an expression plasmids into the Fg14
hepatoma cells results in activation of fibroblast-specific TFs as well as downstream fibroblastsspecific genes. We wanted to determine whether a similar effect can be observed for Twist1 gene.
We were not able to observe significant activation of key fibroblast-specific TFs. Although not
studied in here, we speculate that overexpression of Twist1 in the hepatoma cell line might activate
other fibroblast-specific TFs that work in collaboration with other TFs to define the drive lineagespecific transcriptional regulatory circuitry.
We started with showing that the Twist1 gene is expressed at levels which are 1000-fold
higher than those in the hepatoma cells (Figure 9). We were able achieve high level expression in
mouse Twist1 in the rat hepatoma cells using expression vectors from Origene. The results showed
strong expression of mouse Twist1 gene in the cells compared to non-transfected cells, both in the
pooled transfectants and some of the individual clones analyzed (Figure 11).
Over-expression of the mouse Twistl gene in the hepatoma cell line resulted in activation
of only one fibroblast-specific TFs and two fibroblast-specific downstream genes- Prrx1 and
Sema3a, respectively (Figures 22 and 28) while the other genes, including C-Fos, Shox2, Snai2,
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Sppl and Col1a1 (Figures 23, 24, 25, 26, 27) did not show significant activation in both the pool
and clones.
Several TFs have been reported as master regulators of the epithelial–mesenchymal
transition (EMT) program. These include Twist1, Snail family zinc finger 1 (SNAIL1), Zinc finger
E-box-binding homeobox (ZEB), PRRX1, KLF4, SOX4, and SOX9[118]. Thus, it makes sense to
assume correlation between Snai2, Prrx1, and Twist in the pathways of EMT. The Col1a1 gene,
which is a common marker for fibroblast identity, was not activated by Twist1. A similar
observation took place for Snai2-transfected cells per previous results from our lab, although
Prrx1-transfected cells showed significant activation.
Prrx1 is expressed in mesenchymal tissues in adult mice and studies showed that Prrx1 has
the capability of differentiating mesenchymal precursors. More specifically, Prrx1 was showed to
inhibit adipogenesis by activating TGF-beta signaling[119]. On another note, Twist 1 was also
showed to be a regulator of adipocyte gene expression although not likely to regulate
differentiation[120]. This positive correlation might explain Prrx1 upregulation by overexpression
of Twist1 gene in hepatoma cell line.
We observed a high activation level in some of the clones for Sema3a gene (Figure 28)
which is a member of the semaphorin family and it is secreted by neurons and surrounding tissue
which guides migrating cells and exons in developing systems. It also serves as an endogenous
inhibitor of angiogenesis[121]. A similar condition occurs for Twist 1 gene. Studies showed that
Twist1 is required for Tie2 expression and angiogenesis[122]. This might be a reason why Sema3a
is upregulated by overexpression of Twist1 gene in hepatoma cell line.
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4.2. Twist1 in Diseases
A very important role Twist1 plays besides the role in organogenesis is the expression of
aggressive tumors in a variety of cancer types such as breast cancer[65], hepatocellular
carcinoma[88], prostate cancer[89], gastric cancer[90], oesophageal squamous cell carcinoma[91],
bladder cancer[92] and pancreatic cancer[93]. Twist1 has a presence in cancer initiation,
progression as well as metastasis[57]. Most well-known effects of Twist1 in cancer is the
promotion of cancer cell (epithelial-mesenchymal transition) EMT and metastasis. Metastasis has
many steps including EMT, local invasion, intravasation, transportation, extravasation,
proliferation at another site and production of overt metastatic lesions[94]. Just as it does for
development, Twist1 exhibits a similar behavior by supporting the cells to undergo EMT and move
away to form secondary tumor sites[95].
Although Twist1 plays an important role for many types of cancers, the way it expresses,
functions and the molecular mechanisms affected in this process vary for each type of cancer. HCC
is a metastatic tumor characterized by rapid growth[56]. It has been shown that Twist1
overexpression has a positive correlation with HCC metastasis and a negative correlation with Ecadherin expression[88]. The demonstration of higher levels of Twist1 and lower levels of Ecadherin corresponding to higher metastatic capability implies that Twist1 inhibits E-cadherin
expression and activates EMT alterations[88]. Upregulation of vascular endothelial growth factor
(VEGF) and N-cadherin by Twist1 in HCC points to Twist1’s role in HCC angiogenesis[96].
Another study demonstrated the increased mobility effect of overexpression of Twist1 on HCC
cells[97]. In a previous study[98] involving Twist1 and two other major EMT regulators (Snail
and Slug) the synergistic effects of Twist1 and Snail in enhancing HCC metastasis were observed.
Co-expression of Snail and Twist1 decreased E-cadherin and deteriorated prognosis significantly
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compared to Twist1 expression alone, whereas Slug expression was not significant. Further
verification comes from a study demonstrating Twist1’s effect on increased motility, invasiveness
via inhibiting E-cadherin expression and upregulation of N-cadherin[99].
On a further note, Twist1 gene mutations in human cause Saethre-Chotzen syndrome which
is an autosomal dominant inheritance disease[63].
4.3. Possible Factors Contributing to Variation in Expression Levels
Most of the experimental findings exhibit large variation in expression levels and this
section aims to address possible reasons of why they occur. Firstly, sample acquisition and
handling before the RNA extraction can contribute to variation because of inappropriate sample
collection and processing[123]. For example, incubating (37 °C) freshly-obtained mouse liver
tissue for four hours significantly reduced the measured levels of some mRNAs[124]. Secondly,
assessment of RNA concentration and purity is determined using a UV/Vis spectrometer. Since at
260 nm wavelength DNA can be detected in the case of DNA contamination overestimation of
RNA concentration can occur. The most common way to determine RNA quality is to separate the
RNA sample in an agarose gel and to visualize using a fluorescent dye[125]. This could have been
checked before proceeding to qPCR while making sure reagents are still fresh. Another check that
might have an impact on variability is the presence of more than one DNA fragment. This could
significantly change the result and including melting curve analysis to make sure a single product
is amplified[123]. Yet another factor to reduce the variability happens during data normalization.
We have used GAPDH as reference gene but using multiple genes for normalization has been
shown to reduce variability[126]. There are a couple of software programs to assess reference gene
as both GAPDH and ACTB variation for a wide range of tissues has been shown in the
literature[127]. Yet another reason of variation could be to due technical issues such as qPCR
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instrument, the detection method, the reaction volume, and the liquid dispensing method.
Instrument calibration and regular testing are important. Finally, levels of expression for most
fibroblast genes were close to the detection limit for the RT-qPCR, (> cycle 35) making it likely
that signals obtained could be suspect. .
On another note, fibroblast genes were expressed at very low levels in the hepatoma cells
(often >100 fold lower than in the fibroblasts cells) which possibly explains why the RT-qPCR
data was highly variable between transfected pools and clones.
4.4. Future Directions
In the experiments, for the Twist1 candidate genes where we observed strong activation
we are not certain that the cause is Twist1 binding to promoters of the transcription factor
promoters. This could be determined by a software that predicts transcription factor binding sites
(TFBS) paired with functional assays such as ChIP-Chip and ChIP-Seq to detect the binding site
sequences of Twist1 on promoters. There are several experimental methods to achieve this both in
vitro and in vivo[128]. In vitro methods include Electro-Mobility Shift Assay (EMSA) which uses
non-denaturing polyacrylamide gel as a molecular sieve to separate protein-bound DNA from
unbound DNA, DNase I footprinting/protection assay which combines the cleavage reaction of
DNase I with EMSA, Systematic Evolution of Ligands by EXponential enrichment (SELEX) that
works by monitoring short, random oligonucleotide probes that are recognized by a TFBS of
interest. More recently, in vivo approaches are getting more popular. Chromatin
ImmunoPrecipitation (ChIP) assay is one such method.
Moreover, to reduce Twist1 expression in the Fg14 cells gene knockdown experiments can
be utilized. This experiment would help us find out whether the fibroblast-specific as well as
downstream genes get affected or not. Furthermore, cell culture models can be established to check
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Twist1 expression levels during embryogenesis in normal and Twist1 knockout mice model to
help explain the role of the protein in fibroblast function. Finally, conducting a whole-genome
microarray analysis on the Fg14-Twist1 cells as opposed to Fg14 cells and Rat cells would pinpoint
the degree of genomic remodeling as a result of over expression.
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